+ Click for EPISODE TRANSCRIPT

---

DISCLAIMER: This text is the output of AI based transcribing from an audio recording. Although the transcription is largely accurate, in some cases it is incomplete or inaccurate due to inaudible passages or transcription errors and should not be treated as an authoritative record. Nothing that you read here constitutes advice medical or otherwise. Always consult with a healthcare professional before making changes to a healthcare plan.

Scott Benner 0:00
Hello and welcome to Episode 154 of the Juicebox Podcast. Today's episode is sponsored by Dexcom. To find out more about the Dexcom g five, you can go to dexcom.com Ford slash juicebox. The episode is also sponsored by Omni pod to try a free no obligation demo pod today, go to my Omni pod.com Ford slash juice box.

This is the one you've been waiting for. Shacey Petrovic is back the CEO of insolate of Omni pod of your favorite tubeless insulin pump. She's going to update us on all kinds of stuff, including the imminent release of the new dash PDM. Huge thanks to all of you who sent in questions through Facebook, Twitter, Instagram, and email really should consolidate that somehow. But you guys sent in a bunch of questions for JC and I think I got through all of them. Please remember that nothing you hear on the Juicebox Podcast should be considered advice, medical or otherwise, always consult a physician before making changes to your medical plan.

Shacey Petrovic 1:15
Hi, this is JC JC I

Scott Benner 1:17
Scott, how are you?

Shacey Petrovic 1:19
Hi, Scott. Good. How are you? Good. Thanks.

Unknown Speaker 1:20
You hear me? Okay.

Shacey Petrovic 1:21
I can Yeah. Can you hear me?

Scott Benner 1:23
I'm very good. I can hear you fine. I understand. We're both on a tight schedule today. So that's handy for both of us. Let me jump right in. So we don't waste time because I know we're going to talk about a lot. And I do just want to say one. One thing that has nothing to do what we're talking about, I think that your visits on the podcast are really being heard by people. Because not as many people are calling you Stacy online anymore.

Shacey Petrovic 1:52
That is progress. We're making progress

Unknown Speaker 1:53
here.

Shacey Petrovic 1:57
Wonderful. Well, thank you for you know, helping me correct the, the misunderstanding in the marketplace.

Scott Benner 2:03
I just noticed that recently. I was like I used to just say, Hey, I'm going to be speaking with Shacey Petrovic, remember the whole thing. And then people would say can you please ask Stacey, can you please Stacy, it's happening much less now. So definitely getting your repetition. So where should we start? How about with the new dash PDM? Can you tell me a little bit about that how the FDA submission is going and what we should expect as far as timelines and other details?

Shacey Petrovic 2:25
Yeah, I terrific. You know, we're really excited about dash. This has been a program in the works for a couple years now. And the whole idea with dashes to move to, to leveraging mobile technology in order to drive value for our customer base. So we are modernizing the PDM. And that actually, the PDM will be a locked down cell phone. So have very much the experience of a cell phone in terms of touchscreen, intuitive, modern interaction, really great user interface, a ton of work being done there. And then it also moves the system to Bluetooth communication. And so both the PDM and the pod will communicate via Bluetooth. The great thing about that is it sort of unlocks all the data from the PDM and the pod. So that we can start to really provide, you know, some benefits to our users things like apps, a secondary display app, but that we call Omni pod display on a user's mobile phone. And then also what we call Omni pod view, which is a follower viewer app for caregivers. And so all of that was submitted to the FDA in January and and also as the platform kind of for our future innovations. And so we're now working with the FDA as they progress their review, the plan would be, you know, this goes like most submissions that it would be approved sometime middle of the year, we would move into a limited market release and then move into a full market release towards the end of the year. Okay.

Scott Benner 4:00
And so that process isn't too tough, because I think we talked about it before because this Android device is it's not like you're the only ones in the world using them. They are the base, the base of it is is manufacturers are pretty much at a high rate around the world.

Shacey Petrovic 4:13
Yeah, that's right, millions of these and so that that offers huge benefits to our users. And, you know, that was the trade off that we talked about that in the context of, you know, we will not have an integrated meter in the device any longer, because we're essentially moving to a consumer electronics device. And the huge benefit of that is that, you know, millions of these are manufactured across the globe. So highly reliable, you know, very modern, very much a device that a consumer expects in terms of the experience, and then gives us a lot of flexibility because it's software based gives us a lot of flexibility in terms of how we can over time develop the user interface and really respond to user needs. The downside of course, is the fact that we don't have a meter integrated into the device. We made That choice. Because you know, more and more of our users are using CGM. And more and more of our users are dosing off their CGM. So we could sort of see where the market was going there. And ascencio was great in working with us to ensure that even though it's a separate device, it's highly integrated via Bluetooth, the experiences is seamless in terms of that data, feeding into our bowls, calculator, without any we know, just in an automated fashion. So we thought we could provide, you know, all the benefits of a consumer device and an offset with mobile technology, some of the challenges of having a separate meter, I think

Scott Benner 5:37
you walk the tightrope really well, because I mean, I'll say that there's, it's great that the meters in the Pdn, like it just there's just one less thing to fumble for. But at the same time, I completely understand everything you just said, and I understand the need to be able to move forward with more flexibility, especially because what this means is, if a smaller device comes out later, you know, or, or you guys just want to change. It's a quick, easy change. I think the one concern that I hear amongst people is if I don't have a dexcom, or I'm, or I'm not comfortable dosing from what my Dexcom says, You know, I think I think people feel abandoned, but at the same time, I don't see it that way. So yeah, you know, and I get I get that, you know, what I mean, like, but at the same time, it's not there. And I think, I think a little bit of time will prove that out for them. Because in the end, I think the Android device you're going to provide plus the the new meter is is informed smaller than the than the pay now. Right? So you're, you're carrying less stuff, it

Shacey Petrovic 6:36
just Yes, it's

Scott Benner 6:37
there's two pieces, I

Shacey Petrovic 6:38
guess. That's That's exactly right. And that's that is we did make the PDM, smaller and sleeker. And the SMC a meter itself very small and sleek. So the case and the user experience overall with Bluetooth connectivity, and the auto entry into the Bolus psyche later, very strong user experience. And so we did, we were very thoughtful about it, we recognize that people appreciate the fact that they're integrated. And this will enable us to integrate with all sorts of, you know, meters down the line. And that's the beauty of kind of also moving the data to the mobile phone is that depending on the sensor that people are using, or the generation of Dexcom sensor that the that users are using, they will have that integrated experience on their mobile phone with data and not have to worry about the integration on the hardware,

Scott Benner 7:25
I see somebody coming up really simply with a third party like small leather case that goes around the Android device and holds the meter. And I think that ends everybody's concern. Yeah, because I get being like, when something's been the same way for so long, it I mean, it was my first thought, I think I was I was somewhere with you guys. And I heard it for the first time, maybe like a year and a half ago. And I was like, Oh, God, don't do that. And then as I thought about, you know, and then as I thought about it more, I'm like, well, it only makes sense. We can't keep if you keep combining this medical device with this electronic thing. It's just, there's just going to be too many speed bumps along the way. Well,

Shacey Petrovic 8:01
it's funny, too, because when you do market research, you know, it's just funny, you're we are obviously trying to please as many people as possible with our innovations, and you talk to the existing user base that uses about 80% of our user base actually uses the integrated meter. And they like it. And then you talk to new customers, and they don't actually always like the idea of having to, you know, rely on one meter and not have that choice. And so it's just an interesting thing. As you look across people and what we we definitely see the trend that over the last few years, the BGM choices become less and less important of a factor in the decision making as people kind of get more technologies around, you know, CGM available to them.

Scott Benner 8:46
Yeah, I think that as long as people understand that, because I think Dexcom is still it's interesting how you guys get kind of paired together in people's minds, I think of that as a good thing, because I think you're the most kind of forward thinking companies in both areas. And so but at the same time, like you'll see people talk about all the time, like, hey, Mo, my Omni pod thing, show my Dexcom stuff, and I'm like, does your car show what your TV's watching? Like, like, it's, you know, like, it's an interesting, like, people melded together in the head because they use them together. But at the same time, what I'm hearing is, if I'm right, I'm going to test my blood sugar with this new meter, and Bluetooth, it's going to go right into the PDM. Anyway, so that's the information that goes right in there. If I don't need insulin, I don't actually ever have to pull the Android device out. Do I could just like if I test my blood sugar, it's 100. I just go Oh, okay. And like, put it away. And I'm done. Right? Exactly. Right. And I can see my blood sugar on my phone. I don't have to have the PDM to see my blood sugar or my insulin on board or stuff like that. Is that right?

Shacey Petrovic 9:45
That's right, as well. Yeah. So we have those two apps that I talked about. As a user you'll have Omni pod display, and Omni pod display will show virtually all of your PDM data on your phone in a secondary display app. So you You can just click on your app and it will show you last bolus, insulin on board, kind of all of the key stats that you have on your PDF. And that same information will be available in what we call our Omni pod view app. And so the view app is essentially the follower app. And that will enable caregivers to view a potter's p data remotely. And it will it's the content is pretty much the same, you know, last Bolus, and so on board dashboard, history, all of that stuff will be available on the mobile phone.

Scott Benner 10:30
Okay. And is there in your mind? Is there a path to one day the FDA saying you don't need this lockdown device will let you Bolus through your smartphone? Do you think it ever comes?

Shacey Petrovic 10:42
I do. I do. I think it comes and I don't think it's that far away. And we talked a little bit about this last time that I you know, we've been in active discussions around this. It's the number one request that we get from our customers and are yet to be customers, as people, you know, especially now as we move to a mobile device, which people love because it's discreet. I mean, it is a cell phone looking device, and it's a lockdown cell phone people. The next question intuitively is, you know, where do we go from here? And why can't I just use my cell phone? Now it's a it's a more complex issue. I think we talked about that, too, if you think about all of the use cases that you're designing for. So what happens when you're giving yourself a bolus and you get a telephone call? Or, you know, or you download some app, and it interferes with the the project or the performance of the insulin delivery app? All of those things are security questions and behavior questions that we need to answer for the FDA. And we've got a pretty significant effort underway trying to do that. That's cool.

Scott Benner 11:45
I would imagine, or the cellphone companies involved in those conversations to like Apple and Android D, do they get involved in that part of it or no,

Shacey Petrovic 11:53
they do. And you know, if you think about it, the way that the FDA works, if we wanted to try to get a phone control app out there, we would probably start with one phone or one group of phones because you you really need a deep development effort. And so you would probably do that in conjunction with a phone company. Yeah, that makes sense.

Scott Benner 12:14
Okay, so and so. But your apps that are going to come out to work in conjunction with that, hopefully, by the end of the year around, there'll be Android and Apple available

Shacey Petrovic 12:24
right away their display. And so the first ones to come will be Apple iOS, just the development pathway is a little bit faster for them. But we're already underway on the development tied to Android as well. So those will come as sort of fast followers to the iOS apps. Cool.

Scott Benner 12:39
Okay, great. Do you want to move on to Medicare? Because Because as much as I now think I understand that I still don't think I understand it. I think I understand that something great happened on the political side. Okay, she'll be back in just a second to talk about Medicare, horizon, artificial pancreas address all the questions that you guys sent to me, which are too numerous to mention here. We're also going to talk about the growth of Omni pod as far as their manufacturing goes, and globally. That's right, Australia, I asked about you. But first, let's talk about the Dexcom g five continuous glucose monitor. Actually, I think Dexcom got me back on the show Pretty soon, too. But that's neither here nor there. At the moment. I had a very interesting experience. This weekend, when I spoke at a jdrf event. I was standing in front of a roomful of people explaining concepts that we talked about here on the podcast, like being bold with insulin and Pre-Bolus, and things like that. I could tell by people's faces, how they were nodding along and the questions that they were asking that they were understanding. But then I put up graphs from ardens Dexcom. And when I started pointing and saying, Look here, I Pre-Bolus here, and this happened, the food went in here, and here's how they reacted with each other. This is how I kept her blood sugar stable at 90 during a meal full of carbs. That was the moment man did that just set off fireworks in people's heads. The data that you get back from the dexcom CGM is the key to making great decisions with your type one diabetes, it's the key to understanding how to manipulate insulin. So we're talking and then this one woman raises her hand and says, Well, what do you do while your daughter's at school? And I said the exact same thing she didn't understand. And that's when I was able to explain that Dexcom has a share and follow feature. It's available for Android or Apple phones. When that young mother found out that she could see her child's blood sugar while they were out of the house. The look on her face was absolutely heartwarming. I hope you go to dexcom.com Ford slash juice box to find out more. There are also links in your show notes and at Juicebox podcast.com. Do you want to move on to Medicare?

Shacey Petrovic 14:45
we as a company have been working for I would say three years now on four key initiatives and one is awareness around the product. You know, making sure that people know it's a choice. The second was Customer service is in no order. But customer experience, we felt like through product quality through customer support, we had an opportunity to really drive improvements there and be best in class. And the third is on innovation and you know, accelerating dash to market and the rest of the product pipeline. And then the fourth was on access. And we just really understand how important access is to all of those things to the customer experience as to whether or not we can afford to bring innovation to the market and to awareness access plays a role in all of those things. And so, for three years now, our CEOs top priority has been to get Medicare Part D and everybody in the organization has been involved. Many people across the community, including all of our customer base, we had something like Gosh, 30, or 40,000 letters that came from Omni pod users to CMS and to Congress, professional associations like Ace and endo jdrf, and other advocacy groups, just a ton of people who helped us in accomplishing this and who over the last three years have hung with us and really provided their advocacy on behalf of the community. So all of that resulted in a huge win in early January, where CMS issued guidance that clarified that Medicare Part D sponsors can now provide coverage for the pod. And by the way, not just Omni pod, but other technologies that deliver insulin into the body. So this is a broad when they clarified specifically Omni pod, but it's actually a win for multiple technologies for the community is interesting. I think it may be not intuitive to the community because we were approved under Part D, which is the drug benefit, as opposed to part B, or DMA, which is where all the other insulin pumps are approved. We sort of thought going this way. And so we're really excited about what this could mean for the customer experience. And I can talk a little bit about that. But But I think that's why the community was left thinking, Okay, do I have access today? And do I have access like I do with other insulin pumps? And the answer to both of those questions is not quite. So it's huge news, because you know, of the million and a half people that live with type one diabetes in the United States, almost a third of them, you know, have either Medicare or Medicaid coverage. And this decision gives them a pathway to access. But we've got a lot of work to do between now, and really the fall to make sure that we can get broad access to all of these individuals. So what we'll do now, so we've got this guidance. Now what our job is, is to go to, there's roughly a dozen, plan D sponsors. So these are insurance plans, and providers that basically provide care and coverage to Medicare beneficiaries, and to something like nine of them cover 80 or 90% of the 45 million patients that are covered through Medicare, we'll go to each of them, and negotiate access and pricing. So that starting in 2019, all Medicare beneficiaries will have access to ami pod. And that's the work that's already underway. Our team is off and running with that and making good progress.

Scott Benner 18:17
That process does not sound fun at all. It really doesn't. Does this make it possible for people to one day go into a pharmacy and get their Omni pods.

Shacey Petrovic 18:30
That is the goal. You know, now, CMS has clearly designated as a pharmacy product, we've got today, maybe 10, to 15% of our business going through the pharmacy channel. And what we hear from our, from our users and from their clinicians, is that the experience is just much easier. So in many cases, it's a physician writing an E prescription, you don't have the prior authorization process, you don't have the vendors involved, like you do on a DMV side. That turnaround time is typically you know, a fraction of what it is on the DMV side for a patient who's interested to actually get the product. And so the experience is much, much better both for the clinic, as well as for the user, for the patient. And so we're hopeful that we can bring those same benefits now to a broader group of our customers now that we've got this official designation, and to Medicare and Medicaid beneficiaries, but the vision is that, you know, a physician would write in a prescription, and the patient would go to the pharmacy and pick up their pods where they pick up their insulin and the rest of their supplies. And you don't have to deal with, you know, intermediaries and other more burdensome processes.

Scott Benner 19:44
Would that open up that that processing process for people who are on Medicaid or Medicare or would it just be for them?

Shacey Petrovic 19:51
Yeah. No, it would be for Medicare, Medicaid and commercial patients as we get more and more pharmacy access but the the reason why We sort of linked Medicaid and Medicare is that once you have CMS guidance for Medicare, most Medicaid plans sort of follow the lead on CMS guidance. And so our team is now going to all of these Medicare plan providers, we're also in the process of going to all the Medicaid plans and educating them on CMS guidance, and then doing that pull through at the Medicaid level as well. So we're gonna make good progress this year on both fronts, but probably the big broadening of access occurs in 2019,

Scott Benner 20:32
I can think of a company that I have to talk to frequently to get my thoughts from that I'm very excited never to speak to again, so that's great. I mean, there are,

Shacey Petrovic 20:43
you're not Yeah, you're not the first person to say that to me. And, and that's one of the things that, you know, we we have prioritized the customer experience at insolite. And so, you know, we've invested a lot in improving customer care in staffing at larger levels, and in trying to, you know, make the customer experience across the board improved. And a big piece of that is access, how do you get your products? How do you what sort of burdens Do you have to go through on a monthly or annual basis to do that, and, and pharmacy, for us, at least in the early stages has demonstrated a really improved experience there?

Scott Benner 21:18
No, I think I would completely agree with that. I also think it's nice for you to get to explain it because it feels like when you're you know, when you're at home and you see something on your mind, oh, look, they they said okay to this, that's pretty much what you hear. And then you know, it doesn't happen for a year and a half. And you think, Well, nobody cares. But there's a process in place that needs to be followed that didn't, you know, takes it takes headcount, headcount, it takes effort it takes it takes a lot, you know, to make this happen, right. Just briefly, if you go to my omnipod.com, forward slash juice box, you can get a free, no obligation demo pod. On the pod, we'll send you out a non functioning pod, but you can still adhere to yourself and see what it's like to wear it and get a real feel for the forum and the fit and the comfort. And then from there, if you're happy with it, you contact them back. And they can help you get the process going. That's it no big add my omnipod.com forward slash juice box, you can always find those links in your show notes or at Juicebox. Podcast calm. And in these notes. For this episode, there's also going to be links to clinical trials with on the pod if you want to try to get on their horizon, artificial pancreas trial. There's phone numbers, for those of you who are current customers who want to keep Medicare going, there's gonna be a lot in the show notes this week. So make sure you take a look. Alright, that's it. Back to Shea. See.

Shacey Petrovic 22:40
That's right. And we have, we sort of made those investments ahead of time. So we're already off and running, I think we've actually had discussions with every Part D plan sponsor now. So we're already in the negotiation process. We've also staffed up a hotline and a group within our customer care function to help customers go through the Part D exception process. And so Natalie can provide that information to you if you wanted to put it in your call notes or whatever makes sense. But for people who this year are going to age off into Medicare, we should be able to get them continuity of care while we work through, you know, getting established coverage and access on all these plan sponsors. And for new patients that are coming on that are 65 with the anticipation of this changing in 19, we should also be able to help them so we've got a team of people that are simply just walking those types of people through the exception process and, and we've had good success with that so far,

Scott Benner 23:36
that just honestly gave me chills. That's really exciting that you guys are gonna put the effort into doing that. Thank you. That's, that's really cool. Okay, so speaking of what it takes to ramp up to do more. I joke about this every time you're on there was a moment a number of years ago where I started thinking like, oh, on the pods just gonna go away. And then a whole new group of people came in. And now I think, Wow, they are on fire. Yeah, you so not only are you building a new facility, in mass, but you're expanding in the rest of the world. I'm in Europe, and I'm hoping other places because when we get to our questions at the end from from listeners, there are a lot of people asking from the past, not just in America,

Shacey Petrovic 24:20
I noticed that you so you have a global audience. Scott, fantastic.

Scott Benner 24:23
I have to tell you that some days I look at the map and I think why are people listening there? I don't speak that language. Close. But yeah, it's it is really, the internet is it's everywhere, as you know, JC so it works. It works pretty quickly. But it's um, so when I started hearing back, you know, Canadians, I'm always used to Canadians being like, please stop forgetting us, but because that's I think how they feel. But now, you know, I guess growth is, is good because more people around the world are talking about on the pod. So what are you doing internationally right now and and what's the timelines for that?

Shacey Petrovic 24:57
Well, it's fantastic. You know, we Just a note, we annually we update for the for the investment community, our user base, and we just announced that we finished 2017 between 140 and 145,000 active users, that's a 30% year over year increase in the installed base. So just tremendous growth, which is why we're making these investments in US manufacturing and in the international expansion. Actually, Canada was our first step into becoming a global company. So just about two years ago, now, we acquired the distribution back from GSK in the Canadian market, and then has been hugely successful for us. And we've seen tremendous growth there. We've built a really strong team there, the customer satisfaction scores are very high. And it's just been a tremendous win for us. And so that's when we started to think about, you know, that was successful was a bit of a pilot, and how do we really establish the global footprint that we want to how do we not depend on distributors to deliver the customer experience deliver innovation to the market and determine when and how we enter into new markets. And so we made the decision now almost a year ago, to go direct in our European markets. And so that will happen on July 1 of this year, we're transitioning our European customers to, to insolate from the existing distributor who has said, this is actually a big undertaking, because there's anticipated to be somewhere between 50 and 60,000 customers that we'll be transitioning from if cement to insolate. We've had people on the ground now for quite a while we've got a growing team there, we've got our European headquarters established. And we now have entities across the market in all the markets in which we compete. So really exciting progress. Last week, we were in Vienna, I guess, a week before last in Vienna for attd, which was our first time exhibiting at a European conference as insolate, as opposed to as you know, as IP summit. And so really making great progress there July 1, we will have actually, at that time, were estimated to have somewhere around 65,000 users, and they will become the pod insolate customers. And so really, really excited about that what that does. One is turned us into a global company, by the end of 18, I think, you know, we'll be virtually half and half in terms of how many customers exist internationally versus how many customers exist in the US. And so a lot of our time and energy in intellect is spent on, you know, how do we really make sure that we've got innovation plans that contemplate the global market needs? How do we make sure that we're setting up for success across access, awareness, etc, depending on the unique market needs of these international markets, across Europe, Canada, and other markets. And then the great thing about this is it the term it also allows us to enter into new markets when, when we want to. And so there are a ton of markets, like you mentioned Australia, that are that we know want the pod and we haven't been able to move forward in those markets because of our relationship with ups met. So this now unlocks our capability and doing that as well. And we're looking very hard at new markets in Australia, New Zealand, looking at new markets across Europe, I think, you know, candidly, I think that's going to be a 19 event. Or maybe sometime towards the end of 18. Because we've just got a lot of work to do to make sure that we transition this business successfully and ensure continuity of care for all of the fast growing European markets. And then we'll start to get to work on new market entries

Scott Benner 28:51
where again, you're moving quickly because you had to dissolve that relationship with Epson med to even make these moves. So yeah, and that didn't happen that long ago. So that I think it's good. So Australia, it's got a hold on a little longer and a little longer. Yeah, listen. Here's what I just learned from what you told me about these numbers. I don't charge enough for the ads on the podcast. That's what I just figured out. I didn't hear the rest of it. Jc but I heard that so

Unknown Speaker 29:20
you like it?

Scott Benner 29:22
Well, that is really I mean, that is genuine saying you sent one of my favorite British people out of the country. And and he's now in England working hard on Yeah, Don's gone.

Shacey Petrovic 29:32
Yeah. If you know he had his first child in in the UK, actually.

Scott Benner 29:37
So your business model changed his kids national citizenship was

Shacey Petrovic 29:47
truly global now.

Scott Benner 29:50
Just trying to build a employee around the world. That's excellent. No one knows down but trust me, Dom saved me one time at a dinner meeting. When was being myself and the other people were like, I don't get why we're involved with this guy. And Don was like, I think he's funny. And I was like, thank God.

Unknown Speaker 30:10
That's excellent.

Scott Benner 30:12
So yeah, let's see, I want to, I want to talk a little bit about, about what you guys are doing. Because, you know, people don't, companies don't often build their own merchandise. And so, to me, it sounds like an incredible confidence on the company's part, to build a manufacturing facility, and you're gonna fold your headquarters and like this is all going to happen in one place at some point. Is that is that really the whole thing's gonna be together? That's right.

Shacey Petrovic 30:38
Yeah. And in fact, you know, so it is, it's a massive investment, you're right. And it's a certainly a signal to how confident we are, we're investing probably close to $200 million in Acton in create, you know, acquisition of the site, and all of the building and customization of the site. And then in the automated, there's, this is really amazing the innovation and highly automated manufacturing equipment that we are building, we've got some of the, you know, just tremendously talented automation engineers that are working with our partner, to create all that equipment. And I think, you know, we say, as a company, I said, you know, four things were important to us access awareness, customer experience, and innovation. If customer experience and innovation are truly important to us, then we need to manufacture our own products. And we need to have manufacturing close to r&d, because we're going to be launching a new product every year for the next five years. And you have to get great at technology transfer, process transfer, and the link between manufacturing and innovation. And so all those things led us to say, Hey, we really want to invest in the United States, we're close by and we want to be able to manufacture our own products, this will enable us to, you know, have automation around QC, will enable us to have an innovation line so that we can get really good at transferring innovations from r&d to the facility. And we're doing all of this enact in manufacture in Acton, Massachusetts. So that's where our new plant will be, it's about and, gosh, maybe 15 miles from where we are today. And the facility is enormous, and really is being designed for our needs. And so we'll have a lot of flexibility for growth on the manufacturing side. And we'll be moving all of our functions over there between now and really the beginning of 2019. And we plan to be up and running in manufacturing at the beginning of 19. And we're on track. To do that, it's it's a really exciting move. For us, it's, I don't think there's a lot of companies, frankly, a lot of US companies that are creating manufacturing jobs in the United States. So it's really exciting to be able to make that investment and create jobs right here in Massachusetts. But I think it's even more exciting what this could mean for our ability to deliver innovation to the market more quickly. And what it can mean in terms of the customer experience, because of the quality and reliability and cost of the product out of our US plants.

Scott Benner 33:16
It just makes sense. I mean, if your r&d has an idea about I don't know anything, changing the form factor of the pot, or anything that happens on the inside of it, you taking out a full step of having to go then to the people who tool those machines and make the products and I just sounds like it's obviously more efficient. I'm also thinking on the business side did Acton offered to rename the town insolate when you decided to?

Shacey Petrovic 33:39
I gotta tell you, they were so supportive, I mean, really act in Massachusetts governor, Governor Baker, Charlie Baker, and his life sciences commission. And they just were terrific in terms of helping us find the location in terms of making sure that we had the right structure and incentives in place to make that investment. And the town could not be more welcoming. I mean, even my husband and I have been out to dinner a couple times and act and more people find out that we work for insolate and they come over bring free appetizers or free desserts. I mean, it's just that people are really excited. Yeah. And I think it's, it's, it's a great story, because, you know, they're excited, obviously, for the jobs and the investment, but they're also excited to be associated with the story of insulin and the fact that we actually make a difference in people's lives that we're, we're working to ease the burden associated with this disease. Everybody knows of diabetes, you know, they may not know the specifics, but usually their life is touched by diabetes, so to have kind of that kind of story and that kind of mission in their backyard and people are really excited about it. So it's been just a ton of fun getting to know the town and and, you know, watching our facility go up before our very eyes. I just toured it a couple of weeks ago, and it's really coming together nicely.

Scott Benner 34:53
We're doing a nice conference room and we'll bring the podcasts out there. Do it live for the people in Boston. Yeah,

Shacey Petrovic 34:58
we'll have you know, you have To cut because we're going to have to the manufacturing a walk around hallway with visibility to all manufacturing. So you'll have to come and see the pods coming off the line, once we're up and running in just actually about six months.

Scott Benner 35:13
Exactly. I just got a note today from someone who said, How can we not speaking in Boston this year? And I said, Well, I I don't I don't nobody invited me. And, and but I said that because I'm doing a number of other places. And I always talk to Natalie, I'm like, we should just do it. Like, you know, there's plenty of people to come that want to come out and talk. So it'd be a great way to bring people from the community around to see to see the manufacturing through it. But nevertheless, that's, that's down the road. So you have, I'm going to admit to not understanding your pipeline correctly. Okay, because it came out on a on a chart. A couple of I feel like it's been a while now. And I looked at it and back then I didn't understand the difference between dash and horizon. So I was confused there. And then there was other things happening. But I'd like you to sort of lay out how you think the the timeline of your, of your pipeline looks at the moment.

Shacey Petrovic 36:04
Yeah, fair. Yeah. So first to market obviously, this year will be dash. And that will launch sometime in a limited market release sometime in June or July, it really that's pending FDA clearance, and then go into full market release six months following that, then the next product to market will be Omni pod eu 500. And that's bound to hit the market sometime in 19. And that's our partnership with Lilly to get their concentrated you 500 approved out of Omni pod. And that will be based on the dash platform. So all the benefits that you get with dash plus a very a user interface that's been very much tailored to the 500 user. And the ability to use that concentrate insulin out of the vibes are out of the pod. So that will happen in that in 19, in sometime in 1920, will also come horizon. So I'll set that aside, because I'll talk a little bit more about that. And then 2020 will be u 200. And u 200. Is, is twice the concentration. So you 500 is five times the concentration of you 100. And you 200 is twice the concentration. Both of those products also have very unique, very cool user interfaces that have been designed specifically for you know, a type two user, and in the case of you 500, a you 500 user. So you know, there's just different language used among those user groups, for example, insulin on board, insulin carb ratios, those are terms that are not necessarily widely used or understood among the average type two insulin dependent patient. And so we have worked to kind of simplify the user interface, and to use terminology and workflows that kind of fit, you know, the needs of that that segment. And so that comes in 1920. I'm really excited because you know, in the United States,

Scott Benner 38:02
that's not many people, it just not be present, because you've done it twice. And you're starting to confuse me It's 1920 was a while ago, it's 2020. Okay.

Shacey Petrovic 38:16
2019 or 2020? Yes, 2019 is at you 500. And then 2020 is, is u 200. And those two products basically will help us meet the needs of people who live with type two insulin dependent diabetes, they typically require higher volumes of insulin and daily doses. So rather than make the pod bigger, or the reservoir bigger, to give them more insulin, we have concentrated the influence so that we can keep the form factor and actually still meet their needs with a three day pot change. So that's, that's what comes in 19th 2019. And 2020,

Scott Benner 38:53
we ask a question about that. Do you see any type ones taking advantage of that? Because I'm of the mindset that I would just rather change the pot more frequently. But, but some people aren't. Do you see some people using it for type one, and

Shacey Petrovic 39:07
like, ideally, particularly, you 200 to 500, just kind of unique dissidence on set to action. And it's actually one of Lilly's fastest growing molecules, but it's a smaller, more niche, you know, user group that uses you 500, you 200 has a very similar set of action, and I think will be used by people living with both type one and type two, insulin dependent diabetes. And so I think that you may see that and, and so that's actually why the user interfaces are slightly different. So the 500 user interface is really designed, really with just the type two user in mind. The U 200. user interface is designed for both type one and type two. So there's a slight difference there in terms of how the user interface is presented. So we do think that that product will be used by both patients, both patient groups. So

Scott Benner 39:58
I have one quick question before we get to the listener questions. So you talked about a 30% increase this year in users? Do you have a forecast for next year that you can share? Or is it not public,

Shacey Petrovic 40:10
yet we Yeah, we forecasted a 20% increase in users this year. The difference there, the reason why it's a slightly less, although still really incredible growth is because in Europe, our focus is on transitioning the base as opposed to growing it. So what we're forecasting is that our European customer base will remain relatively flat, revenue goes up, because we're going direct there. But we're just focused entirely on transitioning those existing customers, as opposed to growing in 2018. And then the US will continue to grow, actually, growth accelerates, according to our forecast in 2018 versus 2017. It really just did another terrifically, you know, exciting year for us ahead of us in 2018.

Scott Benner 40:57
What's the most important pathway to growth? Is it? Is it relationships with insurance? Or is it people understanding what the product is? Do you think one's more important than the other? Are they equally?

Shacey Petrovic 41:08
I think they're so intertwined. It's hard to separate them, you know, access to me is it for medical devices is just foundational for, it's foundational for awareness. It's foundational for customer experience. And, you know, it's foundational for cost. And that's part of the customer experience. And so it's why it's been such a huge focus of ours. And it's certainly as we've expanded access, just we've established stronger commercial access, we've established, you know, more Medicaid access, and now we're about to establish really broad Medicare and Medicaid access, I think that is going to help us accelerate significantly. So I think that's huge. And then awareness, we must be crossing a tipping point now in awareness, it's probably because of the Juicebox Podcast, but I keep doing. I do I do think we're at a sort of inflection point for awareness. You know, I was, I can't remember his time, but it was in Nashville for a weekend and I went down to get coffee at the lobby of the hotel, and I was wearing a pretty nondescript black fleece with an omni pod logo on it. And the guy giving me my coffee, he said, Are you a potter? And I said, No, I mean, I worked. And he said, he was a potter, he was so excited about it, he bought my coffee for me, he was just like, it's the best thing ever, you know. And so it just those experiences didn't happen when I first started here at infrared. And now it just seems like, you know, I regularly run into people who are familiar with or actually using Omni pod, which is, is great to see, because that just, you know, sort of compounds on itself once you really hit a certain threshold. Okay.

Scott Benner 42:54
All right. So I'm gonna hit you fast with these these listener questions, because we're down to 20 minutes. All right, we can do it. Okay. I think we've already for dash, we've already covered the launch time, the US limited role in June, hopefully everything by the end of the year 2018. We talked a lot about the apps that will that will work on the user's phones and on caregivers phone. So I think we understand that pretty well. Again, like I said, a lot of people that are trying these things, when they're asking questions, will my dash information, be able to show my Dexcom information. So can I see Dexcom on dash or Dexcom on an app,

Shacey Petrovic 43:32
but you will be able to see you'll have integrated viewing of Dexcom data and Omnipod data via your mobile phone. So we actually made a conscious decision not to do hardware integration, because of what we saw in the market. You know, people were pumped companies were not keeping up with sensor innovation. So you know, you sometimes your pump wouldn't, wouldn't match up with your current gen g five sensor, for example. And we also see in market research that our users oftentimes will go back and forth between different types of sensors or bgms, and sensors. And so we made the conscious decision to go to the mobile phone with our data, so that you could integrate with whatever sensor you're using and integrate with whatever fitness data and other apps that you're using to help manage your your diabetes and your your decisions around blood glucose. So what that means immediately with dash is that if you have an iPhone, you'll be able to have your two widgets right next to each other. So you'll have a Dexcom widget, and you'll have an Omnipod widget right on your phone. So you just, you know, click on your phone, you don't actually even have to go into an app and you'll have your data available and visible right next to each other. And then as we get further along in the development with other sensors, etc. and an even more integrated viewing with Dexcom in terms of data overload, that's all goals for us. But when the product launches, you'll have that type of integration on your mobile phone, so not on the device. But on your mobile phone vertical

Scott Benner 45:02
and insulin on board is visible in the view app. We said yes to that. So that's good. Android we understand will come after apple. But you did you learn from dex coms trip up. So you think you can make it happen faster than they did?

Shacey Petrovic 45:18
I think we can make it happen faster. Yes. In fact that Natalie should be able to follow up with you, we probably even have some sort of forecasts on that. I just don't know it off the top of my head. Okay, so

Scott Benner 45:28
here comes the next question. Once you whenever you say you're going to transfer from one device to another one, something I've paid for already, and you want to give me another one, I saw the question so often, you know, what's the pathway to obtain a new PDM? Or is it is it gonna cost me any money? You know, if I really need one, meaning minds on last legs, or I'm out of warranty, do I get any kind of you know, do I get bumped to the front of the line? How about that kind of stuff? Hey, I just wanted to jump in here and say, if you're new to the podcast, and you just came into here from JC today, where you don't listen every week, but you come in every once in a while, please consider subscribing and trying out some more the episodes, I think you would find a lot of great information. That might be, you know, pretty helpful in your living your day to day life with Type One Diabetes, hearing people's stories, hearing about management ideas, it's good stuff. Let's say this too. We're 45 minutes in, we've got about 15 more minutes to go. If you're excited about what you're hearing from JC about where on the plot is going, please visit my omnipod.com Ford slash juicebox. To try their free no obligation demo pod Get started today was on the pod

what's the pathway to obtain a new PDM.

Shacey Petrovic 46:55
So there will be a pathway for everybody to obtain the new system. And and we're very committed to making that pathway totally accessible. So I wish I could give you more insight than that. But at this point, I can't yet. But as the product launches, it'll become abundantly clear. And our goal is really to have everybody have access to the to the PDM. And if you paid for your existing PDM, we certainly don't want you to have to pay twice, or pay more or anything like that. So we're working on all of those pathways. And as we launch maybe as we get closer to launch, it would make sense for for us to be back on this show really talking about, you know those opportunities, but we fully understand this is a concern, you know, for our customers, and we're going to do the right thing.

Scott Benner 47:42
There you go. I think I know one of the things you guys are hoping to do. And I wish I could say it out loud, but it's very cool.

Shacey Petrovic 47:49
So as we get closer, we'll be shouting it from the rooftops. Hopefully, this podcast,

Scott Benner 47:53
let's see, will new pods be required? So if you have the new PDM, will I need? Like, the question really is I have a stockpile of pods at my house. Are they gonna work? Yeah.

Shacey Petrovic 48:03
And they won't, because either current communication is radio frequency, proprietary radio frequency communication, and this will move to Bluetooth. So there's actually Bluetooth going into the pod as well as the PDM. And so you won't be able to use your new PDM with your old pods and vice versa. Okay, so

Scott Benner 48:21
everybody who's got a zombie apocalypse pile of pods somewhere start using them up and saving are available. I think we're going over why there's no big meter in the PDM. There was a question about when you get under 50 units, why it only says 50 units. And so does the new PDM have the ability to show more specific measurements

Shacey Petrovic 48:47
medium. So as it relates to remaining insulin, it will operate the same way as the current system. So it still will go down to sort of thresholds like 50 plus and 50. Less it won't get more specific than that. I you know, I'm I don't know, Scott, frankly, off the top of my head why that decision was made. But I can certainly look into it.

Scott Benner 49:10
It's got to be something to do with the technology it takes to

Shacey Petrovic 49:12
make measurements. That would be my guess to I don't know, what the technical feasibility is, and and probably some concern over specific accuracy what you know, wanting to make sure that whatever information we're providing is absolutely accurate. And

Scott Benner 49:25
when it says I'm under 30 miles. Let's see. So is there any way to authorize data shares with healthcare provider? New PDO

Shacey Petrovic 49:36
actually, users can do that today through insolate provided gluco. So today, if you use gluco, which we provide to Omni pod users, you can authorize your clinic or your clinician or your physician to see that data. But you'll be able to do that with dash two. So our view app will enable you to share your data with up to five other people so caregivers, school nurses, clinicians, whoever you decide that those five people are. So you'll, you will definitely be able to do that via dash and the Omni pod view app. But you can actually do that today with gluco.

Scott Benner 50:12
For all the people who are hanging on to the things that they love most wins the Is there a drop dead when your PDM your old PDM stops working that there won't be another old PDM replace, like if I don't want the dash, which wasn't a lot of questions, but it was asked a couple of times. So if I don't want the dash, how long am I going to be able to make do with the one I have until

Shacey Petrovic 50:34
you just don't, we don't have plans right now to obsolete the existing platform. So we're not going to force everybody to convert quickly to dash. That said all of the market research would indicate that I think everybody's going to want to convert to dash when they become familiar with the technology and all of its benefits. So we'll see how that goes. But we don't have plans right now to force the conversion at all.

Scott Benner 50:56
Okay, and I can't even remember if we said this. So I'm just gonna ask again, timelines, when does the PDM happen in Canada.

Shacey Petrovic 51:04
So we're looking at we're underway now. So we'll we'll once we get FDA approval, we'll reference that approval for Health Canada. And there's a small bit of development work that needs to happen around millimoles. So you know, they use a different unit of measure in Canada. And so all of those things are kind of underway. But once we get FDA approval will then submit for Health Canada clearance, I'm sorry, FDA clearance will then submit for Health Canada, clearance, and then roll out our distribution plan from there. So sometime probably in early 19, would be my guess.

Scott Benner 51:37
And then the thing we talked about earlier for Australia, you're not going to show up in Australia with all PDM. So they'll when you get that going, that'll be all that'll start with ash, I imagine.

Shacey Petrovic 51:47
You know, I'm not sure about that, because the original registration in Australia was tied to the original platform. So we're evaluating what it would take to update it or launch and then convert at some point. And there's a there's a really growing demand there. So we want to do whatever route to market is going to happen faster. And as you might know, you know, our medical director, Dr. Trang ally is Australia. And she literally asked me about this on a weekly basis, even from her maternity leave. So we're very eager to get this done. She gets personal emails all of us get, you know, patient outreach and community outreach from Australia. And so we want to get there as quickly as we can, that might be with the current platform, and then we'd have to make a plan to convert to the to the new one.

Scott Benner 52:31
I have a contingent of Australian listeners, who are they, they are persistent. So we talked earlier about the reasons why you wouldn't integrate Dexcom with the device like and I think that that's a leftover idea from years and years ago, where that was the how people were thinking about, like, these things are all just going to be together one day. And yeah, and it's just what you said, just made a lot of sense to me. Because if you start combining things, then there's going to be countless iterations of your product, which makes it I think, impossible to service. And then I just think that keeping them the way you described, keeping them apart makes a lot of sense to me.

Shacey Petrovic 53:14
But we want, we want our users to be able to use whatever sensor they want to use, right. And so that could be a G five, it could be a G four g six, when it comes whatever they're currently using. And by doing software integration on your mobile phone that ensures that you can use whatever sensor whatever generation of sensor at whatever period of time that you want. So that's how we were thinking about it. That said, our horizon program is very much a fully integrated product, because we're going to be dosing off of it. It's a complete system. And so that is a completely integrated system. And I don't know if we touched on that in the development pipeline, but that's forecasted right now for the end of 19, early 20s. We're gonna try

Scott Benner 53:55
to save in that for the end JC I want people to listen through.

Shacey Petrovic 53:58
Okay, we'll come back to that.

Scott Benner 54:00
Someone I wish I had the person's name asked this question, because as soon as I saw this question, I thought, Oh, I have thought this so many times. And I already know how you're going to answer it. So it's a little defeating to ask, but I want to say it anyway. I set up a temp, an extended bolus, let's say I say I'm gonna do 10 units 40% now and the rest over an hour, and 25 minutes into my extended bolus, I realized I need all this insulin right now at the moment, I have to cancel the extended bolus, look on the screen, see how much delivered then do the math and then create a new Bolus a lot. This one person I wish I knew their name said Why can't I just choose between cancel and cancel and deliver? And I thought, wow, that's genius. But you can't do that. So tell me why.

Shacey Petrovic 54:44
Well, it's a great You're right. Wait, we didn't do it. I don't know what the technical hurdles are. And I'm embarrassed to say that this is the first time I've heard that feedback because it does make total sense to me. I understand what you're asking. But I know that dash will operate similar Our current system in this way, the two things I will say though, is number one, we've made every function a lot easier in dash. So everything creating a new Bolus, you know, cancelling an extended Bolus, etc. All of that takes a lot less time and a lot less taps. So that process should be easier. And we did add, I know, that's key, that request was key for pediatric population. And we did add two new features to dash specifically for our pediatric population. And the first is zero bazel. And then the other is I see ratios down to one and a 10th. And so I think, though, you know, we did try to add functionality where we could specifically for the pediatric patient population, I'll put that one on the list and see if there's something that we can do about it for future generations.

Scott Benner 55:46
And for people who don't want concentrated insulin, is there any way to Is there any way to make the Omni pod smaller, but make it hold more insulin JC?

Unknown Speaker 55:57
Magic,

Shacey Petrovic 55:58
I can wave a magic wand. Exactly. I would love to I mean, I think first of all, say that, you know, there's always ongoing effort looking at optimizing the size of the pod, we know that people would want that to be, you know, a band aid or whatever, you know, whatever is very small, and, if possible. And so there's a ton of technology, though, in that little pod. And right now, we feel like the space is very optimized. And we'll continue to, you know, to work on making the footprint smaller, etc. But, but really, there was no way to make the reservoir bigger and make the pod smaller, which is why we went concentrate insolence, because we said, well, at least we can keep the same form factor that we know everybody loves. And we can give them effectively more insulin, and just by concentrating it. And so that's where we went. But I will say that we're always looking at how could we make the pod smaller over time. But making the pod smaller and making the reservoir bigger, that's a real challenge.

Scott Benner 56:58
I thought this morning, as I did my daughter's pod change, by the way, in 30 seconds before she ran out the door for school was I wish people could see how easy it is once you really know how to do it. But as I stuck it on her, I really thought I was thinking about our conversation come up in a couple hours. And I thought it is spectacular how much is inside of this thing? And yet, and yet, as a human being when I look at it, I think why can't Why can't like you know, it's it's sometimes you have to remember what you have is pretty good. I guess so?

Shacey Petrovic 57:25
Yeah. Well, and you know, we do things like the drive mechanism for the auto insertion, you know, that that takes up space. And so the trade off would be, you know, manual insertion to maybe reduce the space, but we know that all of our users love auto insertion. So those are the trade offs that we're always contemplating. As we think about next future generations of you know, what the pod could look like and what the pod could be. I'll give you

Scott Benner 57:48
an easy one for your RND to talk about the clicking that happens before the auto insertion. I bet people would love it. If that didn't happen. I don't know if that's possible. I'm assuming that the there's something ramping up inside of it. But I see Yeah, in my daughter's been using it for years and years and years. And she still can't stop herself from counting the collects. So it doesn't always insert at the same amount of clicks. So when it goes in on the one she doesn't expect, she says words you wouldn't expect a 13 year old to say just because because it surprises her. Okay, you know, it's always going to be a big question. I guess that there are I guess most of your users, I'm assuming don't have issues with the adhesive, but the ones who do with any medical device, have it? Do you? Are you working on hypoallergenic versions of the adhesive?

Shacey Petrovic 58:32
Yeah, that's the other thing that we're always working on that, you know, the adhesive is medical grade adhesive. It's always an ongoing battle, though. Because if you look at, you know, we evaluate all of our global complaint rates, and then always look to have various lifecycle engineering efforts to help address any of those and help make sure that we're always driving improvement in performance. And the thing with adhesive is that complaint rates are virtually the same for it's not sticky enough and or sensitivity. They're both very low. But I don't want to discount it because I know it's it's not a good user experience when it occurs. And that's what any any device that's on body that's a wearable with adhesive is battling, can you make it sticky enough? And yet Can you not cause issues for people with sensitive skin and there's there's a small group of people that are always going to have sensitivity towards towards adhesives. And so that's that's what we're balancing always. And there's there's an ongoing lifecycle engineering effort looking at how do you optimize it? He says, we've been underway on that and made some good improvements actually tied to irritation and making sure that we reduce that down. But I think we'll look continue that effort for a long time. I'll

Scott Benner 59:47
tell you that. And I'll just mention this here on the front of my blog is a blog post that I did not write. It's written by a mother of a child who has an incredible reaction to an adhesive and she figured it out. It's it's an interesting process but everyone who refers to that blog post loves it, I'll put a link in the show notes to it. It's you know,

Shacey Petrovic 1:00:07
I've seen it fat, but I will definitely look at it and send it to our r&d group.

Scott Benner 1:00:11
Yeah, it's really interesting. Um, let's see. Okay. What are you guys doing? Do you work on static, which, you know, every when it gets super dry, some people have their on the pods, you know, I guess error, and we call it static. The biggest the best fix I've ever heard is duct tape, which is weird. So can you just put a piece of duct tape on the inside of the pod we get done? Or how does that work?

Shacey Petrovic 1:00:38
I don't want to oversell, we don't have any data, we don't have any confirmed data on the effectiveness of duct tape. But we have had significant research and development effort focus here. And in fact, this season, we tested some a solution that that had really good results. We tested it in limited fashion. But I'm optimistic that next season, we're going to see a different performance as it relates to ESD. You know, as you said, this, this only hits us during cold, dry months. So typically, it starts to ramp up in December and then starts to ramp down in February, as around kind of the back end of the season. But I think I think we've made some really good progress there. And I think our team actually is on the forefront of understanding ESD and wearable devices. And we've just developed a tremendous amount of expertise here. So I think we've, I think we've nailed it. But but we'll see for sure. next season. Yeah. And she said you have to go to a board meeting and like two minutes. So I have two other questions that I will get answers for and read into the podcast. So let me just like end with as much as you can say, in 90 seconds about horizon and where it's at and what we should expect timewise Yeah, great. So horizon, our program is going really, really well. We're now in our third ID or investigative device exemption study. And that's about 120 125 patients studied now all the way down to age two. And our algorithm has performed very well been very safe during day and night in adults, adolescents, pediatrics. And we've had studies looking at it from 36 hours to in kind of more controlled clinical study clinical environments, all the way through to kind of free living conditions in a hotel. We've had a terrific time and range up to 85% in time and range and less than 2% of hypoglycemia. So really, you know, as good as it gets in terms of these early studies of these programs. And we are really excited about getting this one to market forecasting sometime in the late 2019, early 2020 timeframe,

Scott Benner 1:02:48
is the goal to be able to set a user defined blood sugar goal.

Shacey Petrovic 1:02:52
Yes, yes, we will have multiple flexible set points so that you're not sort of limited as you are in some of the current system here. Go tell

Scott Benner 1:03:01
the board you were doing the Juicebox Podcast, I'm sure they'll understand.

Unknown Speaker 1:03:06
I think they will tell him to get out their phones and

Scott Benner 1:03:07
subscribe.

Shacey Petrovic 1:03:09
It's great to talk to you.

Scott Benner 1:03:11
Take care, go ahead and run. Thanks. Hey, hey, I have a few things to say. But after that, there were a couple of your questions that JC and I didn't have time to get to. So I'll address them right after this. huge thank you to JC and on the pod for sponsoring the podcast and to Dexcom for also sponsoring. If you're just here today to find out more about on the pod. I hope you stick around try some other episodes. There are about a bazillion ways to listen to the Juicebox Podcast. Sure you can listen to Juicebox podcast.com. But it is so much easier to listen on your phone Apple or Android phone doesn't matter which one. Let me just tell you a couple of the ways that people listen through iTunes. That's not great because you got to be sitting at your desk. But if you're a desk, not bad Apple users, there's a podcast app on your phone called podcasts. If you don't like that one, there's about a bazillion others. Let me tell you some of the ways that people listen. Pocket cast podcast that castbox I Heart Radio downcast player Fm stagefright pod bean Spotify breaker Castro, some of you listen at Google Play Music, Stitcher eye catcher. There's more echo antenna pod pod kicker pod kicker Pro. Some of you are even streaming it three of VLC people are listening all different kinds ways through QuickTime who's listening through QuickTime. Get yourself a podcast app on your phone. If you're listening through QuickTime. Let me go on and take a minute to thank everyone for listening. Not only are their listeners in the United States and Canada, you are listening in Brazil, Argentina, Peru, Colombia, South Africa, Morocco, Egypt, Saudi Arabia, Yemen, where else Iraq, Turkey, France, Spain, United Kingdom, Ireland, Germany. Poland, Norway, Sweden, Russia, Kazakhstan, who is listening Kazakh Stan, what's up guys it's now China, India, Pakistan, Australia, Indonesia, New Zealand, Japan and South Korea. Seriously, thank you all for listening and for sharing the Juicebox Podcast. I hope you enjoyed this episode with JC I hope you give it on the potter. I hope you give Dexcom a try. But I want to thank you for giving the Juicebox Podcast a try. I saw firsthand this week like I talked about back in the Dexcom ad, I saw firsthand what it must be like for you to listen to the show. I saw that in person. And I am more motivated than ever to keep this podcast going. And now the questions we didn't have time to get to. The first question I wasn't able to get to is about applying for clinical trials with Omni pod. I've put the instructions for that in the show notes of your podcast player. And if for some reason you use one of the apps that is funky With shownotes you can go to Juicebox podcast.com. Find this episode. It is Episode 154. And the information will be there also. The next question was about beeping on the pod. So for instance, you put on a new pod and it reminds you I think it's two hours later that you've put on a new pod that has a safety feature that the FDA requires. Why can't you silence it without the PDM? Interestingly enough, ami pod did tell me that at one point they thought to build that functionality into the pod like you could tap the pod to stop the beeping. But it was a cost prohibitive idea to add something to the pod that could register a tap. The shorter answer is that the Omni pod tubeless insulin pump has moments where it tells you to pay attention to the fact that you're wearing an insulin pump. This is FDA required. One of those times is for instance after a pod change. Also for hazard alarms like occlusions low reservoir or an expiring pot, the FDA thinks and frankly I agree that there are times when you have to be reminded that you're wearing an insulin pump. Those that I just listed are are great examples. In the end, you can't as a user decide that you don't want those alarms you can on some pumps but on those pumps remember you are tethered to the pump so the pump is always with you with an omni pod. You might put on a new pump in your kitchen and then go outside in your backyard for three hours. You just don't want to not be getting insulin and not know it. And there are some times when your attention needs to be drawn back round you're busy listening. Here is the only pot is so good at helping you to forget that you have type one diabetes, sometimes it has to remind you